Biomedical nanomaterials:
Gespeichert in:
| Weitere Verfasser: | , |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Weinheim, Germany
Wiley-VCH
2016
|
| Schlagworte: | |
| Online-Zugang: | FRO01 UBG01 Volltext |
| Beschreibung: | Cover; Title Page; Copyright; Contents; List of Contributors; Chapter 1 Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials; 1.1 Introduction; 1.2 Commonly Utilized NMs in Pharmaceutical Research; 1.2.1 Natural NMs; 1.2.1.1 Lipid-Based NMs; 1.2.1.2 Protein-Based NMs; 1.2.1.3 Polysaccharide-Based NMs; 1.2.2 Synthetic NMs; 1.2.2.1 Diversity of Synthetic NMs in Forms; 1.2.2.2 Drug Release Behaviors; 1.2.3 Inorganic NMs; 1.2.4 Other NMs; 1.3 In vivo Biodistribution and the Evolving Targeting Principles for NMs; 1.3.1 Organ Distribution versus Cell-Specific Targeting 1.3.2 Targeting Delivery Strategies1.4 Processing NMs by the Biological Systems; 1.4.1 Anatomic Basis of NMs' in vivo Biodistribution Behavior; 1.4.2 Factors Affecting in vivo Biodistribution of NMs; 1.4.2.1 Size; 1.4.2.2 Zeta Potential; 1.4.2.3 Shape and Deformability; 1.4.2.4 Hydrophilicity and Hydrophobicity; 1.4.3 Metabolism and Elimination of NMs; 1.4.3.1 Common Metabolism; 1.4.3.2 Degradable versus Nondegradable NMs; 1.4.3.3 Free Drug versus Drug Encapsulated by NMs; 1.5 Rational Design of Long-Circulating NMs; 1.5.1 NMs with Optimal Physicochemical Characters 1.5.2 Surface Modification to Improve the Intrinsic Features of NMs1.6 Mathematic Simulation of NM-Mediated Cancer Drug Delivery; 1.6.1 Progress: From Experiment to Simulation; 1.6.2 Compartment Models for PK Assessment of NMs; 1.6.3 Physiologically Based Compartment Models; 1.6.3.1 Protocols of Building a PBPK Model for NMs; 1.6.3.2 Examples; 1.6.4 Brief Summary; 1.7 Experimental PK Data of the Applied NMs; 1.7.1 PK Data of NMs Without Drugs; 1.7.2 PK Differences Between Drugs Encapsulated by Different NMs; 1.7.3 Reciprocal Blood and Tissue PK 1.7.4 PK Differences Between Different Components of the Drug-NM System1.7.5 PK Variations Among Different Routes of Administration; 1.8 Perspectives; 1.8.1 Development of NMs; 1.8.2 Pharmacokinetic Study and Model Development; References; Chapter 2 Targeted Dendrimers for Cancer Diagnosis and Therapy; 2.1 Introduction; 2.2 Targeted Dendrimers for Cancer Therapy; 2.2.1 Low Molecular Weight Ligand-Modified Dendrimers; 2.2.1.1 Folic Acid-Modified Dendrimers; 2.2.1.2 Carbohydrate-Modified Dendrimers; 2.2.1.3 Biotin-Modified Dendrimers; 2.2.1.4 Riboflavin-Modified Dendrimers 2.2.1.5 Estrogen-Modified Dendrimers2.2.2 Macromolecular Ligand-Modified Dendrimers; 2.2.2.1 Antibody-Modified Dendrimers; 2.2.2.2 Transferrin (Tf)- and Lactoferrin (Lf)-Modified Dendrimers; 2.2.2.3 EGF- and Fibroblast Growth Factor (FGF)-Modified Dendrimers; 2.2.2.4 Peptide-Modified Dendrimers; 2.2.2.5 Aptamer-Modified Dendrimers; 2.2.2.6 Hyaluronic Acid (HA)-Modified Dendrimers; 2.2.3 Dual-Targeting Ligand-Modified Dendrimers; 2.3 Targeted Dendrimers for Cancer Diagnosis; 2.3.1 Targeted Dendrimers in CT; 2.3.2 Targeted Dendrimers in SPECT; 2.3.3 Targeted Dendrimers in MRI. - Includes bibliographical references and index |
| Beschreibung: | 1 online resource |
| ISBN: | 3527694390 3527694439 9783527694396 9783527694433 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV043769694 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 160916s2016 |||| o||u| ||||||eng d | ||
| 020 | |a 3527694390 |9 3-527-69439-0 | ||
| 020 | |a 3527694439 |9 3-527-69443-9 | ||
| 020 | |a 9783527694396 |c Online |9 978-3-527-69439-6 | ||
| 020 | |a 9783527694433 |9 978-3-527-69443-3 | ||
| 035 | |a (ZDB-35-WIC)ocn957318452 | ||
| 035 | |a (OCoLC)958836583 | ||
| 035 | |a (DE-599)BVBBV043769694 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-861 | ||
| 082 | 0 | |a 610.28 | |
| 084 | |a VE 9850 |0 (DE-625)147163:253 |2 rvk | ||
| 100 | 1 | |a Zhao, Yuliang |4 edt | |
| 245 | 1 | 0 | |a Biomedical nanomaterials |c edited by Yuliang Zaho and Youqing Shen |
| 264 | 1 | |a Weinheim, Germany |b Wiley-VCH |c 2016 | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a Cover; Title Page; Copyright; Contents; List of Contributors; Chapter 1 Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials; 1.1 Introduction; 1.2 Commonly Utilized NMs in Pharmaceutical Research; 1.2.1 Natural NMs; 1.2.1.1 Lipid-Based NMs; 1.2.1.2 Protein-Based NMs; 1.2.1.3 Polysaccharide-Based NMs; 1.2.2 Synthetic NMs; 1.2.2.1 Diversity of Synthetic NMs in Forms; 1.2.2.2 Drug Release Behaviors; 1.2.3 Inorganic NMs; 1.2.4 Other NMs; 1.3 In vivo Biodistribution and the Evolving Targeting Principles for NMs; 1.3.1 Organ Distribution versus Cell-Specific Targeting | ||
| 500 | |a 1.3.2 Targeting Delivery Strategies1.4 Processing NMs by the Biological Systems; 1.4.1 Anatomic Basis of NMs' in vivo Biodistribution Behavior; 1.4.2 Factors Affecting in vivo Biodistribution of NMs; 1.4.2.1 Size; 1.4.2.2 Zeta Potential; 1.4.2.3 Shape and Deformability; 1.4.2.4 Hydrophilicity and Hydrophobicity; 1.4.3 Metabolism and Elimination of NMs; 1.4.3.1 Common Metabolism; 1.4.3.2 Degradable versus Nondegradable NMs; 1.4.3.3 Free Drug versus Drug Encapsulated by NMs; 1.5 Rational Design of Long-Circulating NMs; 1.5.1 NMs with Optimal Physicochemical Characters | ||
| 500 | |a 1.5.2 Surface Modification to Improve the Intrinsic Features of NMs1.6 Mathematic Simulation of NM-Mediated Cancer Drug Delivery; 1.6.1 Progress: From Experiment to Simulation; 1.6.2 Compartment Models for PK Assessment of NMs; 1.6.3 Physiologically Based Compartment Models; 1.6.3.1 Protocols of Building a PBPK Model for NMs; 1.6.3.2 Examples; 1.6.4 Brief Summary; 1.7 Experimental PK Data of the Applied NMs; 1.7.1 PK Data of NMs Without Drugs; 1.7.2 PK Differences Between Drugs Encapsulated by Different NMs; 1.7.3 Reciprocal Blood and Tissue PK | ||
| 500 | |a 1.7.4 PK Differences Between Different Components of the Drug-NM System1.7.5 PK Variations Among Different Routes of Administration; 1.8 Perspectives; 1.8.1 Development of NMs; 1.8.2 Pharmacokinetic Study and Model Development; References; Chapter 2 Targeted Dendrimers for Cancer Diagnosis and Therapy; 2.1 Introduction; 2.2 Targeted Dendrimers for Cancer Therapy; 2.2.1 Low Molecular Weight Ligand-Modified Dendrimers; 2.2.1.1 Folic Acid-Modified Dendrimers; 2.2.1.2 Carbohydrate-Modified Dendrimers; 2.2.1.3 Biotin-Modified Dendrimers; 2.2.1.4 Riboflavin-Modified Dendrimers | ||
| 500 | |a 2.2.1.5 Estrogen-Modified Dendrimers2.2.2 Macromolecular Ligand-Modified Dendrimers; 2.2.2.1 Antibody-Modified Dendrimers; 2.2.2.2 Transferrin (Tf)- and Lactoferrin (Lf)-Modified Dendrimers; 2.2.2.3 EGF- and Fibroblast Growth Factor (FGF)-Modified Dendrimers; 2.2.2.4 Peptide-Modified Dendrimers; 2.2.2.5 Aptamer-Modified Dendrimers; 2.2.2.6 Hyaluronic Acid (HA)-Modified Dendrimers; 2.2.3 Dual-Targeting Ligand-Modified Dendrimers; 2.3 Targeted Dendrimers for Cancer Diagnosis; 2.3.1 Targeted Dendrimers in CT; 2.3.2 Targeted Dendrimers in SPECT; 2.3.3 Targeted Dendrimers in MRI. - Includes bibliographical references and index | ||
| 650 | 4 | |a Biomedical materials | |
| 650 | 0 | 7 | |a Nanostrukturiertes Material |0 (DE-588)4342626-8 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Biomaterial |0 (DE-588)4267769-5 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Biomaterial |0 (DE-588)4267769-5 |D s |
| 689 | 0 | 1 | |a Nanostrukturiertes Material |0 (DE-588)4342626-8 |D s |
| 689 | 0 | |8 1\p |5 DE-604 | |
| 700 | 1 | |a Shen, Youqing |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druckausgabe |z 3-527-33798-9 |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9783527694396 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
| 912 | |a ZDB-35-WIC | ||
| 940 | 1 | |q UBG_PDA_WIC | |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029180853 | ||
| 883 | 1 | |8 1\p |a cgwrk |d 20201028 |q DE-101 |u https://d-nb.info/provenance/plan#cgwrk | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9783527694396 |l FRO01 |p ZDB-35-WIC |q FRO_PDA_WIC |x Verlag |3 Volltext | |
| 966 | e | |u https://onlinelibrary.wiley.com/doi/book/10.1002/9783527694396 |l UBG01 |p ZDB-35-WIC |q UBG_PDA_WIC |x Verlag |3 Volltext | |
Datensatz im Suchindex
| _version_ | 1804176591145664512 |
|---|---|
| any_adam_object | |
| author2 | Zhao, Yuliang Shen, Youqing |
| author2_role | edt edt |
| author2_variant | y z yz y s ys |
| author_facet | Zhao, Yuliang Shen, Youqing |
| building | Verbundindex |
| bvnumber | BV043769694 |
| classification_rvk | VE 9850 |
| collection | ZDB-35-WIC |
| ctrlnum | (ZDB-35-WIC)ocn957318452 (OCoLC)958836583 (DE-599)BVBBV043769694 |
| dewey-full | 610.28 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 610 - Medicine and health |
| dewey-raw | 610.28 |
| dewey-search | 610.28 |
| dewey-sort | 3610.28 |
| dewey-tens | 610 - Medicine and health |
| discipline | Chemie / Pharmazie Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04917nmm a2200553zc 4500</leader><controlfield tag="001">BV043769694</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">160916s2016 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3527694390</subfield><subfield code="9">3-527-69439-0</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3527694439</subfield><subfield code="9">3-527-69443-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527694396</subfield><subfield code="c">Online</subfield><subfield code="9">978-3-527-69439-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783527694433</subfield><subfield code="9">978-3-527-69443-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-35-WIC)ocn957318452</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)958836583</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV043769694</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-861</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610.28</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">VE 9850</subfield><subfield code="0">(DE-625)147163:253</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Zhao, Yuliang</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Biomedical nanomaterials</subfield><subfield code="c">edited by Yuliang Zaho and Youqing Shen</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim, Germany</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">2016</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Cover; Title Page; Copyright; Contents; List of Contributors; Chapter 1 Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials; 1.1 Introduction; 1.2 Commonly Utilized NMs in Pharmaceutical Research; 1.2.1 Natural NMs; 1.2.1.1 Lipid-Based NMs; 1.2.1.2 Protein-Based NMs; 1.2.1.3 Polysaccharide-Based NMs; 1.2.2 Synthetic NMs; 1.2.2.1 Diversity of Synthetic NMs in Forms; 1.2.2.2 Drug Release Behaviors; 1.2.3 Inorganic NMs; 1.2.4 Other NMs; 1.3 In vivo Biodistribution and the Evolving Targeting Principles for NMs; 1.3.1 Organ Distribution versus Cell-Specific Targeting</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">1.3.2 Targeting Delivery Strategies1.4 Processing NMs by the Biological Systems; 1.4.1 Anatomic Basis of NMs' in vivo Biodistribution Behavior; 1.4.2 Factors Affecting in vivo Biodistribution of NMs; 1.4.2.1 Size; 1.4.2.2 Zeta Potential; 1.4.2.3 Shape and Deformability; 1.4.2.4 Hydrophilicity and Hydrophobicity; 1.4.3 Metabolism and Elimination of NMs; 1.4.3.1 Common Metabolism; 1.4.3.2 Degradable versus Nondegradable NMs; 1.4.3.3 Free Drug versus Drug Encapsulated by NMs; 1.5 Rational Design of Long-Circulating NMs; 1.5.1 NMs with Optimal Physicochemical Characters</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">1.5.2 Surface Modification to Improve the Intrinsic Features of NMs1.6 Mathematic Simulation of NM-Mediated Cancer Drug Delivery; 1.6.1 Progress: From Experiment to Simulation; 1.6.2 Compartment Models for PK Assessment of NMs; 1.6.3 Physiologically Based Compartment Models; 1.6.3.1 Protocols of Building a PBPK Model for NMs; 1.6.3.2 Examples; 1.6.4 Brief Summary; 1.7 Experimental PK Data of the Applied NMs; 1.7.1 PK Data of NMs Without Drugs; 1.7.2 PK Differences Between Drugs Encapsulated by Different NMs; 1.7.3 Reciprocal Blood and Tissue PK</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">1.7.4 PK Differences Between Different Components of the Drug-NM System1.7.5 PK Variations Among Different Routes of Administration; 1.8 Perspectives; 1.8.1 Development of NMs; 1.8.2 Pharmacokinetic Study and Model Development; References; Chapter 2 Targeted Dendrimers for Cancer Diagnosis and Therapy; 2.1 Introduction; 2.2 Targeted Dendrimers for Cancer Therapy; 2.2.1 Low Molecular Weight Ligand-Modified Dendrimers; 2.2.1.1 Folic Acid-Modified Dendrimers; 2.2.1.2 Carbohydrate-Modified Dendrimers; 2.2.1.3 Biotin-Modified Dendrimers; 2.2.1.4 Riboflavin-Modified Dendrimers</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">2.2.1.5 Estrogen-Modified Dendrimers2.2.2 Macromolecular Ligand-Modified Dendrimers; 2.2.2.1 Antibody-Modified Dendrimers; 2.2.2.2 Transferrin (Tf)- and Lactoferrin (Lf)-Modified Dendrimers; 2.2.2.3 EGF- and Fibroblast Growth Factor (FGF)-Modified Dendrimers; 2.2.2.4 Peptide-Modified Dendrimers; 2.2.2.5 Aptamer-Modified Dendrimers; 2.2.2.6 Hyaluronic Acid (HA)-Modified Dendrimers; 2.2.3 Dual-Targeting Ligand-Modified Dendrimers; 2.3 Targeted Dendrimers for Cancer Diagnosis; 2.3.1 Targeted Dendrimers in CT; 2.3.2 Targeted Dendrimers in SPECT; 2.3.3 Targeted Dendrimers in MRI. - Includes bibliographical references and index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biomedical materials</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Nanostrukturiertes Material</subfield><subfield code="0">(DE-588)4342626-8</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Biomaterial</subfield><subfield code="0">(DE-588)4267769-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Biomaterial</subfield><subfield code="0">(DE-588)4267769-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Nanostrukturiertes Material</subfield><subfield code="0">(DE-588)4342626-8</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Shen, Youqing</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druckausgabe</subfield><subfield code="z">3-527-33798-9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9783527694396</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-35-WIC</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">UBG_PDA_WIC</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029180853</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9783527694396</subfield><subfield code="l">FRO01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">FRO_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://onlinelibrary.wiley.com/doi/book/10.1002/9783527694396</subfield><subfield code="l">UBG01</subfield><subfield code="p">ZDB-35-WIC</subfield><subfield code="q">UBG_PDA_WIC</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV043769694 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:34:37Z |
| institution | BVB |
| isbn | 3527694390 3527694439 9783527694396 9783527694433 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029180853 |
| oclc_num | 957318452 958836583 |
| open_access_boolean | |
| owner | DE-861 |
| owner_facet | DE-861 |
| physical | 1 online resource |
| psigel | ZDB-35-WIC UBG_PDA_WIC ZDB-35-WIC FRO_PDA_WIC ZDB-35-WIC UBG_PDA_WIC |
| publishDate | 2016 |
| publishDateSearch | 2016 |
| publishDateSort | 2016 |
| publisher | Wiley-VCH |
| record_format | marc |
| spelling | Zhao, Yuliang edt Biomedical nanomaterials edited by Yuliang Zaho and Youqing Shen Weinheim, Germany Wiley-VCH 2016 1 online resource txt rdacontent c rdamedia cr rdacarrier Cover; Title Page; Copyright; Contents; List of Contributors; Chapter 1 Pharmacokinetics and Pharmacodynamics (PK/PD) of Bionanomaterials; 1.1 Introduction; 1.2 Commonly Utilized NMs in Pharmaceutical Research; 1.2.1 Natural NMs; 1.2.1.1 Lipid-Based NMs; 1.2.1.2 Protein-Based NMs; 1.2.1.3 Polysaccharide-Based NMs; 1.2.2 Synthetic NMs; 1.2.2.1 Diversity of Synthetic NMs in Forms; 1.2.2.2 Drug Release Behaviors; 1.2.3 Inorganic NMs; 1.2.4 Other NMs; 1.3 In vivo Biodistribution and the Evolving Targeting Principles for NMs; 1.3.1 Organ Distribution versus Cell-Specific Targeting 1.3.2 Targeting Delivery Strategies1.4 Processing NMs by the Biological Systems; 1.4.1 Anatomic Basis of NMs' in vivo Biodistribution Behavior; 1.4.2 Factors Affecting in vivo Biodistribution of NMs; 1.4.2.1 Size; 1.4.2.2 Zeta Potential; 1.4.2.3 Shape and Deformability; 1.4.2.4 Hydrophilicity and Hydrophobicity; 1.4.3 Metabolism and Elimination of NMs; 1.4.3.1 Common Metabolism; 1.4.3.2 Degradable versus Nondegradable NMs; 1.4.3.3 Free Drug versus Drug Encapsulated by NMs; 1.5 Rational Design of Long-Circulating NMs; 1.5.1 NMs with Optimal Physicochemical Characters 1.5.2 Surface Modification to Improve the Intrinsic Features of NMs1.6 Mathematic Simulation of NM-Mediated Cancer Drug Delivery; 1.6.1 Progress: From Experiment to Simulation; 1.6.2 Compartment Models for PK Assessment of NMs; 1.6.3 Physiologically Based Compartment Models; 1.6.3.1 Protocols of Building a PBPK Model for NMs; 1.6.3.2 Examples; 1.6.4 Brief Summary; 1.7 Experimental PK Data of the Applied NMs; 1.7.1 PK Data of NMs Without Drugs; 1.7.2 PK Differences Between Drugs Encapsulated by Different NMs; 1.7.3 Reciprocal Blood and Tissue PK 1.7.4 PK Differences Between Different Components of the Drug-NM System1.7.5 PK Variations Among Different Routes of Administration; 1.8 Perspectives; 1.8.1 Development of NMs; 1.8.2 Pharmacokinetic Study and Model Development; References; Chapter 2 Targeted Dendrimers for Cancer Diagnosis and Therapy; 2.1 Introduction; 2.2 Targeted Dendrimers for Cancer Therapy; 2.2.1 Low Molecular Weight Ligand-Modified Dendrimers; 2.2.1.1 Folic Acid-Modified Dendrimers; 2.2.1.2 Carbohydrate-Modified Dendrimers; 2.2.1.3 Biotin-Modified Dendrimers; 2.2.1.4 Riboflavin-Modified Dendrimers 2.2.1.5 Estrogen-Modified Dendrimers2.2.2 Macromolecular Ligand-Modified Dendrimers; 2.2.2.1 Antibody-Modified Dendrimers; 2.2.2.2 Transferrin (Tf)- and Lactoferrin (Lf)-Modified Dendrimers; 2.2.2.3 EGF- and Fibroblast Growth Factor (FGF)-Modified Dendrimers; 2.2.2.4 Peptide-Modified Dendrimers; 2.2.2.5 Aptamer-Modified Dendrimers; 2.2.2.6 Hyaluronic Acid (HA)-Modified Dendrimers; 2.2.3 Dual-Targeting Ligand-Modified Dendrimers; 2.3 Targeted Dendrimers for Cancer Diagnosis; 2.3.1 Targeted Dendrimers in CT; 2.3.2 Targeted Dendrimers in SPECT; 2.3.3 Targeted Dendrimers in MRI. - Includes bibliographical references and index Biomedical materials Nanostrukturiertes Material (DE-588)4342626-8 gnd rswk-swf Biomaterial (DE-588)4267769-5 gnd rswk-swf Biomaterial (DE-588)4267769-5 s Nanostrukturiertes Material (DE-588)4342626-8 s 1\p DE-604 Shen, Youqing edt Erscheint auch als Druckausgabe 3-527-33798-9 https://onlinelibrary.wiley.com/doi/book/10.1002/9783527694396 Verlag URL des Erstveröffentlichers Volltext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk |
| spellingShingle | Biomedical nanomaterials Biomedical materials Nanostrukturiertes Material (DE-588)4342626-8 gnd Biomaterial (DE-588)4267769-5 gnd |
| subject_GND | (DE-588)4342626-8 (DE-588)4267769-5 |
| title | Biomedical nanomaterials |
| title_auth | Biomedical nanomaterials |
| title_exact_search | Biomedical nanomaterials |
| title_full | Biomedical nanomaterials edited by Yuliang Zaho and Youqing Shen |
| title_fullStr | Biomedical nanomaterials edited by Yuliang Zaho and Youqing Shen |
| title_full_unstemmed | Biomedical nanomaterials edited by Yuliang Zaho and Youqing Shen |
| title_short | Biomedical nanomaterials |
| title_sort | biomedical nanomaterials |
| topic | Biomedical materials Nanostrukturiertes Material (DE-588)4342626-8 gnd Biomaterial (DE-588)4267769-5 gnd |
| topic_facet | Biomedical materials Nanostrukturiertes Material Biomaterial |
| url | https://onlinelibrary.wiley.com/doi/book/10.1002/9783527694396 |
| work_keys_str_mv | AT zhaoyuliang biomedicalnanomaterials AT shenyouqing biomedicalnanomaterials |